Meta-analysis of prophylactic entecavir or lamivudine against hepatitis B virus reactivation
Journal Title: Annals of Hepatology - Year 2016, Vol 15, Issue 4
Abstract
Introduction and aim. Studies suggest that entecavir and lamivudine are useful as prophylactics against hepatitis B virus (HBV) reactivation in patients undergoing chemotherapy or immunosuppressive therapy, but which drug is more effective is unclear. Here we meta-analyzed available evidence on relative efficacy of prophylactic entecavir or lamivudine therapy in patients with chronic or resolved hepatitis B infection who were undergoing chemotherapy or immunosuppressive therapy. Material and methods. Two reviewers searched PubMed, EMBASE and Google Scholar as well as reference lists in relevant articles to find studies published between January 2005 and May 2015 that met inclusion and exclusion criteria. Data on HBV reactivation, HBV-related hepatitis and all-cause mortality were extracted from the studies and meta-analyzed. Results. A total of eight studies involving 593 patients were included in the meta-analysis, which was performed using a fixed-effect model since no significant heterogeneity was found. Entecavir was associated with significantly lower risk of HBV reactivation than lamivudine (RR 0.29, 95% CI 0.17 to 0.52) as well as lower risk of HBV-related hepatitis (RR 0.11, 95% CI 0.03 to 0.40). The two drugs were associated with similar risk of all-cause mortality (RR 1.12, 95% CI 0.54 to 2.35). Egger’s test suggested no significant publication bias in the meta-analysis. Conclusions. The available evidence suggests that entecavir is more effective than lamivudine for preventing HBV reactivation and HBVrelated hepatitis in patients with chronic or resolved HBV infection who are undergoing chemotherapy or immunosuppressive therapy.
Authors and Affiliations
Chun Yang, Bo Qin, Zhe Yuan, Limin Chen, Hong-yu Zhou
Keywords
Related Articles
- EP ID EP78594
- DOI 10.5604/16652681.1202910
- Views 142
- Downloads 0
On the cusp of change: New therapeutic modalities for HCV
We are at the cusp of significant new alternatives for the treatment of chronic hepatitis C. Among more than 100 drugs in development, some are ready to be approved and in the market as soon as next year. The protease in...
Endoscopic Management of Primary Sclerosing Cholangitis
Primary sclerosing cholangitis (PSC) remains a rare but potentially devastating chronic, cholestatic liver disease. PSC causes obstruction of intra- and/or extra-hepatic bile ducts by inflammation and fibrosis, leading t...
Hemorrhagic liver cyst rupture: An unusual life-threatening complication of hepatic cyst and literature review
[b]Background & aims[/b]. Hemorrhagic rupture is an extremely rare complication of hepatic cyst. Its incidence, gravity and treatment modalities are inadequately covered in the literature. [b]Material and met...
Uncommon localization of amyloidosis in gallbladder: Description of a case and brief literature review
Amyloidosis is a rare disease that is caused by extracellular deposits of amorphous, insoluble fibrillar protein, which often occur in the kidneys, the heart, the nervous system, the digestive tract, especially the hepat...
Primary hepatic neuroendocrine tumour requiring live donor liver transplantation: case report and concise review
Primary hepatic neuroendocrine tumours are rare tumours effecting relatively young patients. As metasta-tic neuroendocrine tumours to the liver are much more common, extensive investigations are crucial toexclude a prim...